Observation on Administration of Propofol at Different Titration Endpoints (OAPDTE)

December 1, 2024 updated by: SanQing Jin

The Impact of Different Titration Endpoints of Propofol on Hemodynamics and Stress During the Induction Phase of General Anesthesia

Propofol has a rapid onset and short duration of action, making it widely used for induction of general anesthesia. However, its prominent drawback is circulatory depression. Our research team previously proposed an individualized dosing method for the titration of propofol. We then compared the effects of different titration rates of propofol on hemodynamics and stress during general anesthesia induction. It was found that the incidence of hypotension during the induction period was lower in the 0.5 mg/kg/min group, with lower stress levels and faster postoperative recovery. However, this group still had a 25.3% incidence of hypotension. Therefore, we plan to further study the differences in hemodynamics, depth of anesthesia, stress response, and postoperative recovery in three groups of patients induced with a constant infusion rate of propofol at 0.5 mg/kg/min titrated to an OAA/S score of 1, an OAA/S score of 2, and BIS ≤ 60, combined with remifentanil 2 μg/kg. This study aims to explore the appropriate propofol titration endpoint during general anesthesia induction to maintain stable perioperative haemodynamics and achieve rapid postoperative recovery.

Study Overview

Detailed Description

Propofol can rapidly induce sleep in patients, creating favorable conditions for tracheal intubation, and is widely used for the induction of general anesthesia for tracheal intubation. However, its prominent drawback is circulatory depression. In clinical practice, propofol is still commonly administered for the induction of general anesthesia as a single intravenous bolus at the recommended dose (2-2.5 mg/kg). This method does not take into account individual differences and easily causes hypotension. In addition, target-controlled infusion under BIS monitoring is used in some cases. However, this approach requires high standards of equipment, has limited clinical applicability, and there is still controversy over whether the targetcontrolled model accurately reflects the concentration of propofol in blood or brain tissue.A 2020 retrospective study by Eric Y. et al. showed that the anesthetic induction dose of propofol for elderly patients was not adequately adjusted according to recommendations, resulting in an excessive actual dose. There are also studies on titrated administration of propofol, but the endpoints for titrated administration are still unclear.

Hypotension during the induction period has been identified as an independent predictor of adverse clinical outcomes. Early studies suggested that a mean arterial pressure (MAP) of <50-55 mmHg or a reduction in systolic blood pressure (SBP) or MAP by more than 40-50% from baseline can cause organ dysfunction.As research into the dangers of hypotension deepens, the minimum value that hypotension may cause damage is continuously increasing, and the harm brought by mild hypotension is increasingly being taken seriously. The impact of induced hypotension during the induction period on patients is related to the severity, duration of hypotension, and the patient's baseline condition.

Hypotension during the induction period of anesthesia is largely preventable and should be prevented. Therefore, finding appropriate endpoints for propofol titration can reduce the incidence of hypotension during the induction period, which is of ignificant significance for improving the prognosis of surgical patients.

Common methods for monitoring the depth of anesthesia during the induction period of general anesthesia include observer-based evaluations, such as the Observer's Assessment of Alertness/Sedation (OAA/S) score, and machinebased evaluations, such as the Bispectral Index (BIS) score.

The OAA/S score is a commonly used clinical observation tool that is simple and convenient to operate, requiring no additional equipment. It mainly assesses the depth of sedation by giving verbal commands and tactile stimuli to the patient. Various studies have shown that it correlates closely with machinebased indices for monitoring the depth of anesthesia, such as the BIS and the Index of Consciousness (IOC). As a straightforward, cost-effective method for monitoring the depth of anesthesia, the OAA/S score is closely related to clinical manifestations and is particularly suitable for monitoring the depth of anesthesia during the induction period.

BIS (Bispectral Index) is a quantitative electroencephalogram (EEG) parameter that transforms the frequency, amplitude, and phase characteristics of the EEG through fast Fourier transformation, providing a numerical value between 0 (suppressed state) and 100 (awake state) to quantify different depths of anesthesia. However,the BIS value is influenced by various factors;neuromuscular blockers can interfere with BIS readings,while esmolol and epinephrine can increase BIS readings. Some studies have shown that BIS monitoring does not reduce intraoperative awareness and the amount of anesthetic agents used.Since the calculation and analysis of EEG data require time, there is a delay of approximately 30.09 ± 18.73 seconds in monitoring the depth of anesthesia with BIS. Therefore, BIS has limitations in monitoring the depth of anesthesia.

Currently, many studies use BIS for monitoring the depth of anesthesia during surgery. Some research has shown that titrated administration of propofol based on BIS monitoring (40-60) during the induction period of general anesthesia does not differ in propofol dosage and incidence of hypotension compared to conventional single-dose administration. This prompts the critical inquiry: Is BIS an appropriate measure for assessing the depth of anesthesia during the induction period of general anesthesia? In the first phase of our previous research, we proposed an individualized dosing strategy for slow constant-rate infusion of propofol, using an OAA/ S score of 1 as the titration endpoint. Through a randomized controlled trial comparing the hemodynamic effects of slow infusion of propofol (1 mg/kg/ min) versus the traditional single-dose administration (2 mg/kg, 250 mg/min) during the induction period of general anesthesia, we found that the titrated administration of propofol not only mitigated the extent of blood pressure reduction, but also decreased the overall amount of propofol required during the induction phase.

In the second phase, we further designed a randomized controlled doubleblind trial to explore appropriate titration infusion rate. We studied the effects of titrated induction at infusion rates of 2 mg/kg/min, 1 mg/kg/min, and 0.5 mg/ kg/min on hemodynamics, brain activity, blood concentration of propofol, and stress response. We found that all three titration methods achieved the required depth of anesthesia for tracheal intubation. The 0.5 mg/kg/min group had a more stable blood concentration curve of propofol, lower incidence of hypotension and low BIS during the induction period, lower stress levels, and shorter recovery time after surgery.Based on the research, we found that the 0.5 mg/kg/min group still had a 25.3% incidence of hypotension, with the proportion of cases with mean arterial pressure <65 mmHg as high as 47.3%. Therefore, we hypothesize that adopting an OAA/S score of 2 as the titration endpoint might be more reasonable.

This study aims to compare the differences between using different OAA/S scores and BIS value for guiding titrated administration of propofol during the induction period of general anesthesia. We seek to explore a reasonable and feasible titration endpoint for propofol to reduce the incidence of hypotension during induction, maintain stable perioperative vital signs, and facilitate rapid postoperative recovery.

The protocol involves a planned enrollment of 258 patients scheduled for surgery under tracheal intubation and general anesthesia. They will be randomly divided into 3 groups of 86 patients each according to a random number table. During the induction of anesthesia, the pump operator will adjust propofol at a rate of 0.5 mg/kg/min based on the envelope group (Groups O, T, B), titrating to the respective endpoints (OAA/S score of 1, OAA/S score of 2, BIS ≤ 60). Propofol will then be adjusted to a maintenance dose of 2-4 mg/ kg/h, combined with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg. Tracheal intubation will commence 2 minutes after muscle relaxant administration. Researchers will observe hemodynamic changes and EEG activity throughout the process, adjusting medications to maintain stable hemodynamics as much as possible.

After confirming the successful tracheal intubation, the investigators will give participants machine-controlled ventilation, and the total intravenous anesthesia(TIVA) will be given with propofol, remifentanil, and cis-atracurium. During the operation, remifentanil will be injected with a constant rate of 0.2ug/ kg/min, and propofol will be injected with a fluctuating rate of 2-8mg/kg/h (the pump injection rate will be adjusted according to blood pressure and BIS, and the rate of remifentanil can be adjusted if necessary) to maintain BIS between 40-60.Fluid therapy will be performed according to the participants' hemodynamics and intraoperative conditions. After extubation, participants will be sent to the postoperative recovery room; a follow-up visit will be performed the next day,and a telephone return visit will be performed on the 30th day.

Researchers recorded the preoperative day Recovery Quality (Qor-15) scores for each participant, preoperative anxiety (VAS) scores upon entry; maximum and minimum blood pressure during anesthesia induction, BIS values corresponding to different OAAS scores and the lowest BIS value during induction. and corresponding times of propofol titration to OAA/S scores; total doses of propofol, remifentanil, rocuronium, and vasopressors during induction; pupil size and reflex assessments at four time points (before sleep, at titration endpoint, before intubation, after intubation); auditory evoked potentials (AEP) and electroencephalogram monitoring before propofol administration and at titration endpoint; blood draws at three time points (pre-induction, titration endpoint, 30 seconds post-tracheal intubation) for glucose and stress indicators catecholamines (epinephrine, norepinephrine); postoperative assessment of intraoperative awareness and postoperative memory, and cardiovascular events within 30 days postoperatively recorded with Recovery Quality (Qor-15) scores.

Parameters recorded during induction include systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), BIS value, cardiac function parameters [heart rate variability (HRV), stroke volume (SV), stroke index (SVI), cardiac output (CO), cardiac index (CI)), oxygen delivery parameters (oxygen delivery (DO2), oxygen delivery index (DO2I)], peripheral vascular resistance parameters [systemic vascular resistance (SVR), systemic vascular resistance index (SVRI)], volume parameters [stroke volume variation (SVV), pulse pressure variation (PPV), increase in stroke volume (SV)], auditory evoked potential parameters [brain stem auditory evoked potentials (BAEP):latency and amplitude of waves III, V; middle latency auditory evoked potentials (MLAEP): latency and amplitude of waves Pa, Nb], and EEG parameters (power spectrum of β, α, θ, and σ brain waves).

Blinded design: After assigning intervention measures, blinding is implemented for subjects and researchers (principal investigator, main anesthesiologist, postanesthesia care unit physician, postoperative follow-up physician).The principal investigator of the research team generates allocation numbers and recruits participants. During induction, the specific grouping of anesthesia patients is unknown, and each patient receives a complete assessment of OAA/S scores.

The research team instructs the anesthesiologist in charge of adjusting the infusion pump to: collect experimental envelopes from the research assistant in advance, set up the infusion pump, position the pump away from the primary observers and main anesthesiologist, and adjust propofol administration based on grouping, combined with assessments by the principal investigator or BIS values. Propofol administration is stopped upon reaching the titration endpoint, followed by maintenance doses, and administration of remifentanil and rocuronium is given. The doses of propofol and induction times are recorded. During induction, the anesthesiologist follows instructions from the principal investigator to administer additional vasopressors or propofol and does not participate in postoperative follow-up tasks.

Study Type

Interventional

Enrollment (Estimated)

258

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age 18-60 years.
  2. Elective surgery with planned endotracheal intubation under general anesthesia.
  3. ASA classification of I or II,with heart function classified as 1 or 2.
  4. Body Mass Index (BMI) 18-30 kg/m².

Exclusion Criteria:

  1. Severe cardiac, pulmonary, hepatic, or renal diseases (heart function classification greater than 3 / respiratory failure / liver failure / renal failure).
  2. Malignant arrhythmias: atrial flutter, atrial fibrillation, atrioventricular block, frequent ventricular premature beats, multifocal ventricular premature beats, ventricular premature beats R on T, ventricular flutter, and ventricular fibrillation.
  3. Expected difficulty with intubation, hypoalbuminemia, hypertension, or diabetes mellitus.
  4. Patients with a high risk of aspiration due to a full stomach, gastrointestinal obstruction, or pregnancy.
  5. Patients with schizophrenia, epilepsy, Parkinson's disease, intellectual disabilities, etc.
  6. Alcohol abusers or those who have been using sedatives or analgesics long-term.
  7. Allergic to propofol or its emulsion.
  8. Currently participating in a clinical trial that conflicts with this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group O
Titrated administration of propofol to an OAA/S score of 1 as the endpoint.
Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 1, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
Experimental: Group T
Titrated administration of propofol to an OAA/S score of 2 as the endpoint.
Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 2, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
Active Comparator: Group B
Titrated administration of propofol to a BIS value ≤ 60 as the endpoint.
Propofol is titrated at a rate of 0.5 mg/kg/min to achieve a BIS value ≤ 60, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of a 30% decrease in MAP
Time Frame: During the procedure of anesthesia induction
Incidence of a 30% decrease in MAP during induction with three different titration endpoints
During the procedure of anesthesia induction

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of cases with MAP < 65 mmHg
Time Frame: During the procedure of anesthesia induction
Proportion of cases with MAP < 65 mmHg during induction in three groups
During the procedure of anesthesia induction
Anesthesia depth
Time Frame: During the procedure of anesthesia induction
Anesthesia depth during induction in three groups (BIS values,pupil size and reaction to light,EEG patterns,auditory evoked potentials)
During the procedure of anesthesia induction
Tracheal intubation conditions
Time Frame: After finish intubation
Differences of the tracheal intubation conditions of patients among the three groups
After finish intubation
Blood glucose
Time Frame: During the procedure of anesthesia induction
Blood glucose before induction,at the end of titration,and 30 seconds after endotracheal intubation in three groups
During the procedure of anesthesia induction
Stress hormones
Time Frame: During the procedure of anesthesia induction
Stress indicators (catecholamines: adrenaline,noradrenaline) before induction,at the end of titration,and 30 seconds after endotracheal intubation in three groups.
During the procedure of anesthesia induction
Mean Arterial Pressure(MAP)
Time Frame: During the procedure of anesthesia induction
Changes in MAP during induction in three groups
During the procedure of anesthesia induction
Heart Rate(HR)
Time Frame: During the procedure of anesthesia induction
Changes in HR during induction in three groups
During the procedure of anesthesia induction
Cardiac Index(CI)
Time Frame: During the procedure of anesthesia induction
Changes in CI during induction in three groups
During the procedure of anesthesia induction
Stroke Volume Index(SVI)
Time Frame: During the procedure of anesthesia induction
Changes in SVI during induction in three groups
During the procedure of anesthesia induction
Systemic Vascular Resistance Index(SVRI)
Time Frame: During the procedure of anesthesia induction
Changes in SVRI during induction in three groups
During the procedure of anesthesia induction
Propofol dosage
Time Frame: During the procedure of anesthesia induction
Propofol dosage during induction in three groupsThe dosage of propofol (Reach the end of the titration, complete the tracheal intubation, and complete the operation) and usage of vasoactive drugs in the three groups
During the procedure of anesthesia induction
Recovery time
Time Frame: From surgery completion to first recovery
Postoperative recovery time
From surgery completion to first recovery
Length of hospital stay after surgery
Time Frame: From surgery completion to actual hospital discharge,assessed up to 30 days
Hospital stay time from operation completion to actual hospital discharge
From surgery completion to actual hospital discharge,assessed up to 30 days
Cognitive and memory function
Time Frame: Postoperative Day 1 and Day 30
Modified Brice Questionnaire,Three-Word Recall Test,AD-8 Self-Assessment for Cognitive Impairment
Postoperative Day 1 and Day 30
Recovery quality
Time Frame: Preoperative Day 1 and postoperative Day 1 and Day 30
Postoperative recovery score using 15-item quality of recovery scoring system(QoR-15)
Preoperative Day 1 and postoperative Day 1 and Day 30
The occurrence of important cardiovascular events
Time Frame: Within 30 days after surgery
The occurrence of important cardiovascular events during the perioperative period
Within 30 days after surgery
Induction time
Time Frame: After finish operation
Induction time in the three groups
After finish operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Sanqing Jin, MD, The Sixth Affiliated Hospital, Sun Yat-sen University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 20, 2025

Primary Completion (Estimated)

June 20, 2025

Study Completion (Estimated)

August 20, 2025

Study Registration Dates

First Submitted

November 9, 2024

First Submitted That Met QC Criteria

November 9, 2024

First Posted (Actual)

November 12, 2024

Study Record Updates

Last Update Posted (Estimated)

December 4, 2024

Last Update Submitted That Met QC Criteria

December 1, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anesthesia, General

Clinical Trials on Titrated administration of propofol to an OAA/S score of 1 as the endpoint

Subscribe